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ABSTRACT 
Obesity and type 2 diabetes mellitus (T2DM) progress worldwide with detrimental effects on several 
physiological systems including bone tissue mainly by affecting bone quality. Several gut hormones 
analogues have been proven potent in ameliorating bone quality. In the present study, we used the 
leptin receptor-deficient db/db mice as a model of obesity and severe T2DM to assess the extent of 
bone quality alterations at the organ and tissue levels. We also examined the beneficial effects of gut 
hormone therapy in this model by using a new triple agonist ([D-Ala²]GIP-Oxm) active at the GIP, 
GLP-1 and glucagon receptors. As expected, db/db mice presented with dramatic alterations of bone 
strength at the organ level associated with deterioration of trabecular and cortical microarchitectures 
and an augmentation in osteoclast numbers. At the tissue level, these animals presented also with 
alterations of bone strength (reduced hardness, indentation modulus and dissipated energy) with 
modifications of tissue mineral distribution, collagen glycation and collagen maturity. The use of [D-
Ala²]GIP-Oxm considerably improved bone strength at the organ level with modest effects on 
trabecular microarchitecture. At the tissue level, [D-Ala²]GIP-Oxm ameliorated bone strength 
reductions with positive effects on collagen glycation and collagen maturity. This study provides 
support for including gut hormone analogues as possible new therapeutic strategies for improving 
bone quality in bone complications associated to T2DM.  
 
 
Keywords: Type 2 diabetes mellitus, [D-Ala²]GIP-Oxm, bone quality, bone strength, db/db mice 
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INTRODUCTION 
Obesity is a major predisposing factor for the development of type 2 diabetes mellitus (T2DM). 
It accounts for 80-85% of the overall risk of developing T2DM and underlies the marked worldwide 
increase in the incidence of this condition [1]. In the last decade, several studies reported that obesity 
and T2DM make an important impact on the skeleton. Despite inconsistencies in the reporting of the 
effects of body mass on bone metabolism, bone impairments are clearly evident in established rodent 
models of obesity and insulin resistance [2-5]. Several bone-related hormones are altered in these 
animal models of obesity including leptin, which serves as an important regulator of body weight [6, 7]. 
The long form of the leptin receptor is encoded by the db gene and a recessive mutation in this gene 
has been shown to affect the intracellular domain of the single membrane-spanning receptor [8]. 
Although leptin appears to bind to its receptor in mutant homozygous db/db mice [9], defective 
intracellular signal transduction attenuates leptin function, leading to a characteristic phenotype of 
severe obesity and diabetes [10, 11]. As such, leptin receptor-deficient (db/db) mice represent a 
genetic rodent model of spontaneous obesity as well as genetically-inherited T2DM. Indeed, db/db 
mice exhibit early onset obesity with hyperinsulinemia, hyperlipidaemia, insulin resistance and 
pancreatic -cell dysfunction culminating in severe age-related hyperglycemia [10, 11]. These animals 
also exhibit macrovascular complications and nephropathy, complications often found in human T2DM 
patients [12]. Several investigators have studied the impact of leptin on bone physiology reporting a 
dual action of central and peripheral leptin on bone mass and strength using either ob/ob mice, db/db 
mice or leptin receptor-deficient fa/fa rats [5, 13-17]. However, an important aspect of these animals is 
the obesity-diabetes that could possibly play a role in the reduction of bone strength, in addition to the 
direct actions of leptin signalling pathways in bone.  
 
In response to nutrient intake, two incretin hormones, namely glucose-dependent 
insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are released by enteroendocrine 
cells in the gastrointestinal tract. The primary physiological target of these gut hormones is the 
pancreatic β cell, where these hormones stimulate insulin secretion and thereby contribute to the 
control blood glucose concentrations [18]. As such, the action of incretin hormones have therapeutic 
potential for the treatment of type 2 diabetes, as indicated by the current clinical use of GLP-1 
mimetics [19]. Recently, a growing body of evidence suggests that incretins could also be beneficial 
for bone strength. Indeed, the importance of GIP and GLP-1 signalling in normal bone regulation was 
revealed in genetically-modified knockout and transgenic mice where the ablation of GIP or GLP-1 
receptors led to dramatic alterations of trabecular and cortical microarchitecture as well as detrimental 
effects on tissue material properties of bone [20-26]. Furthermore, administration of GIP or GLP-1 
agonists to healthy or type 1 diabetic rodent models significantly improved tissue material properties 
within a month [23, 27]. Recently, it has also been demonstrated that polymorphism at the GIP 
receptor locus was associated with lower bone mineral density and greater incidence of non-vertebral 
fractures [28]. Taken together, these data suggest beneficial effects of GIP and GLP-1 signalling on 
bone. Nonetheless, endogenous incretins are a substrate of dipeptidyl peptidase-4 (DPP-4) and the 
gut hormones are rapidly cleaved by this serine protease enzyme, yielding the inactive truncated 
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forms of these peptides. In order to circumvent DPP-4 activity, several stable long-acting incretin 
analogues have been developed and evaluated for their glucose-lowering and insulin-releasing 
properties [29].  
 
Intestinal enteroendocrine cells produce several other hormones, including oxyntomodulin 
(Oxm), which is a 37-amino acid peptide, derived from the proglucagon gene and co-secreted with 
GLP-1 following feeding. Oxm exerts its effects by binding to and co-activating both glucagon and 
GLP-1 receptors to stimulate insulin secretion and reduce blood glucose [30, 31]. Oxm is also involved 
in the regulation of energy expenditure and food intake, leading to reduction of body weight [32]. Much 
recent research suggests that stable analogues of Oxm might be useful for the treatment of obesity-
diabetes [29]. In addition, several N-terminally modified stable GIP peptides, such as (D-Ala
2
)GIP [33], 
have significant antidiabetic activity. Based on these observations, [D-Ala
2
]GIP-Oxyntomodulin has 
been generated by our group in order to activate GIP, GLP-1 and glucagon receptors. The efficacy of 
[D-Ala
2
]-GIP-Oxm as a triple agonist and to reduce hyperglycaemia has been established in high fat-
fed mice, which exhibit a mild form of diabetes [34]. Taking into consideration the capacity of this 
peptide to activate GIP and GLP-1 receptor pathways, important for bone strength, [D-Ala
2
]GIP-
Oxyntomodulin is viewed as potential therapeutic agent in management of bone alterations in 
diabetes.  
The aims of the present study were (i) to conduct a thorough investigation of micro-
architectural and material properties of bone in leptin receptor deficient mice, that represent a severe 
form of T2DM, and (ii) to assess whether the multiple agonist peptide [D-Ala
2
]GIP-Oxm could 
represent a useful means of improving bone quality and strength in this condition [35].  
 
 
MATERIAL AND METHODS 
[D-Ala²]GIP-Oxm  
[D-Ala²]GIP-Oxm was purchased from GL Biochem Ltd. (Shanghai, China), and identified by matrix-
assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). Briefly, 1.5 µl 
of peptide (1 mg/ml) solution was dispensed onto a well of a 100-well stainless steel MALDI plate and 
allowed to dry at room temperature. Matrix solution (1.5 µl; 10 mg/ml of α-cyano-4-hydroxycinnamic 
acid in acetonitrile; Sigma-Aldrich, Poole, UK) was added to the dried peptides and the mixture was 
again left to dry. The molecular mass of peptide was determined using a Voyager-DE BioSpectrometry 
Workstation (PerSeptive BioSystems, Framingham, MA, USA) and recorded as mass-to-charge (m/z) 
ratio vs percentage intensity of peak. The observed molecular mass for [D-Ala²]GIP-Oxm was 4472.3 
Da corresponding to theoretical value of 4473.0 Da. Characteristics of [D-Ala²]GIP-Oxm are presented 
in Table 1.  
  
Animals 
Eleven-week-old male db/db mice (mouse strain BKS.Cg-+Lepr
db
/+Lepr
db
/OlaHsd) were obtained from 
Harlan Ltd (Harlan LTD., Blackthorn, UK). These animals carry an autosomal recessive mutation on 
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chromosome 4 that results in leptin receptor deficiency. Age- and sex-matched lean wild type animals 
(n=10; mouse strain BKS.Cg-Dock7
m
+/+Lepr
db
 /OlaHsd) from Harlan with the same genetic 
background were used as controls. Male db/db mice were randomly allocated into two groups 
(n=10/group) that received [D-Ala
2
]-GIP-Oxm (50 nmol/kg bw) or saline vehicle (0.9%, w/v, NaCl) once 
daily for 21 days. This dose was chosen on the basis of positive results obtained with [D-Ala²]GIP-
Oxm in on our previous studies in high fat fed mice [34]. In order to dissociate possible direct effects 
on bone from actions arising from improved glycaemic control we decided to use the same dose (50 
nmol/kg bw) even though db/db mouse present with a much more severe form of diabetes associated 
with insulin resistance, beta-cell dysfunction and islet degeneration [36]. Lean mice were treated with 
saline vehicle for the same period of time. 
Mice were caged individually in an air-conditioned room at 22 ± 2°C with 12 h light: 12 h dark cycle 
with free access to standard rodent diet (10% fat, 30% protein, 60% carbohydrate; Trouw Nutrition, 
Cheshire, UK). Body weight, food consumption, non-fasting blood glucose and plasma insulin 
concentrations were monitored regularly during the 21-day experimental period in diabetic mice. An 
overnight fasted glucose tolerance (18 mmol/kg bw; ip) test was carried out at the end of the study as 
described previously [34]. Plasma glucose was determined by the glucose oxidase method using 
Analox analyser GM-9 with Analox instruments glucose reagent. Plasma insulin was determined by a 
modified dextran-coated charcoal radioimmunoassay (RIA) [37].The mice were also administered 
calcein (10 mg/kg bw; ip) 9 and 2 days before being culled by inhalation of CO2, to estimate the levels 
of newly formed bone. After necropsy, tibias and femurs were collected and cleaned of soft tissue. 
Tibias were fixed with a formalin-based fixative whilst femurs were stored in 70% ethanol. All 
experiments were approved by the local animal care and welfare committee and conducted according 
to the principles of laboratory animal care (NIH publication no.85-23, revised 1985), the United 
Kingdom Office regulations (UK Animals Scientific Procedures Act 1986 revised in January 2013) and 
the European Union directive 2010/63/EU.   
 
Dual-Energy X-ray absorptiometry (DEXA)  
Bone mineral density (BMD, g/cm
2
), bone mineral content (BMC, g) and total body fat (g) were 
measured with a Lunar PIXImus DEXA scanner (Inside Outside Sales, Wisconsin, U.S.A.). Mice were 
anaesthetised with isoflurane and pentobarbital sodium (10 μl/g bw) and then placed on a specimen 
tray. The animals were exposed to low energy X-rays and a high-resolution picture (0.18 x 0.18 mm 
pixel size) was captured of the x-rays hitting a luminescent panel. The whole body was scanned and 
regions of interests (ROIs) were manually drawn over the spine, tibias or whole body. Quality control 
was performed on daily intervals before acquiring data and calibration of the DEXA machine was 
performed using the phantom provided by the manufacturer. 
 
Microcomputed tomography (microCT) 
MicroCT analysis was performed on tibias with a Skyscan 1172 microtomograph (Bruker MicroCT, 
Kontich, Belgium) operated at 70 kV, 100 µA, 340-ms integration time. The isotropic pixel size was 
fixed at 3.75 µm, the rotation step at 0.25° and exposure was done with a 0.5-mm aluminium filter. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
6 
 
Each 3D reconstruction image dataset was binarized using global thresholding. Trabecular parameters 
were assessed in the proximal secondary spongiosa 0.5mm below the growth plate and extending 
2mm down. Bone volume (BV/TV, in %), trabecular number (Tb.N, /mm), trabecular thickness (Tb.Th, 
in µm) and trabecular separation (Tb.Sp, in µm) were determined with the CTan software (Bruker 
MicroCT). Cortical parameters were assessed at the midshaft tibia. Cortical VOIs extended on 1-mm 
centred at the midshaft tibia. Total cross-sectional area (Tt.Ar, in mm²), medullary area (Ma.Ar, in 
mm²), cortical bone area (Ct.Ar, in mm²), cortical area fraction (Ct.Ar/Tt.Ar, in %), average cortical 
thickness (Ct.Th, in µm) and cortical porosity (Ct.Po, in %) were measured with a lab-based routine 
running in Matlab 8.4 (Mathworks, Natick, MA). All these parameters were determined according to 
guidelines and nomenclature proposed by the American Society for Bone and Mineral Research [38].  
 
Bone histomorphometry 
After microCT scans, tibias were cut at the mid-diaphysis and embedded, undecalcified in poly 
(methylmethacrylate) (pMMA) at 4°C to preserve enzyme activities [39]. In order to assess trabecular 
tissue, longitudinal sections of the proximal tibia segment were performed. On the other hand, for 
cortical assessment, we cut perpendicularly to the long bone axis the upper part of the distal segment. 
For each animal, four non serial sections (~50 m apart) were left unstained for the measurement of 
calcein-based parameters and four additional sections were stained for the osteoclastic tartrate 
resistant acid phosphatase (TRAcP) as previously described [40]. Only TRAcP-positive nucleated cells 
in contact with bone were counted as osteoclasts. The trabecular region of interest (ROI) was located 
in the secondary spongiosa 0.5 mm below the growth plate on a height of 2 mm. Standard bone 
histomorphometrical nomenclatures, symbol and units were used as described in the guidelines of the 
American Society for Bone and Mineral Research [41]. The identity of the section was not revealed 
until the end of all measurements. 
 
Circularized light microscopy 
Longitudinal sections of the upper part of the tibia (14µm thick) were observed with an home-made 
circularly polarized light mounted on an Olympus AX-60 microscope (Olympus France, Rungis, 
France). Regions of interest were positioned on cortical bone. Briefly, two circular polarizers were 
inserted in the light path, one below the specimen and the second one above the specimen. These 
two circularizers were equipped with crossed Nicol’s prism and a /4 compensator to eliminate the 
Maltese cross effect. Circularly polarized lights detect the anisotropy of bone through “bright” and 
“extinct” signals owing to birefringence of collagen [42]. For quantitation of birefringence signal, 
illumination intensity and the threshold for distinguishing bright and extinct signal were kept constant 
for all specimens; then percent area occupied by bright birefringent signals at the proximal and middle 
tibia was quantitated with ImageJ.  
 
Three-point bending 
Three-point bending experiments were performed on femurs to assess bone strength at the organ 
level. Prior to mechanical testing, femurs were rehydrated in saline overnight at 4°C. Measurements 
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were done with a constant span length of 10 mm on an Instron 5942 (Instron, Elancourt, France). The 
press head as well as the two support points were rounded to avoid shear load and cutting. Femurs 
were positioned horizontally with the anterior surface facing downward, centred on the support and the 
pressing force was applied vertically to the midshaft of the bone. A pre-load of 1N was applied to 
ensure correct positioning of the femur. Each bone was tested with a loading speed of 2 mm.min
-1
 until 
failure with a 500N load cell as previously published [43]. The load-displacement curve was acquired 
with the Bluehill 3 software (Instron). Ultimate load, ultimate displacement, stiffness and total absorbed 
energy were computerized according to previously published equations [44].  
 
Fourier-transform infrared microscopy (FTIRM) 
After three-point bending experiments, femurs were cross-sectionally cut at the midshaft using a 
diamond saw (Accutom, Struers, Champigny sur Marne, France) and embedded undecalcified in 
polymethylmethacrylate at 4°C as previously reported [39]. Cross-sections (4µm thickness) of the 
midshaft femur were sandwiched between BaF2 optical windows. Spectral analysis were obtained on a 
Bruker Vertex 70 spectrometer (Bruker optics, Ettlingen, Germany) interfaced with a Bruker Hyperion 
3000 infrared microscope as previously reported [20]. For FTIR analysis at site of bone formation, 12 
spectra on each bone were acquired between double calcein labelling and analysed with the Opus 
Software (release 6.5, Bruker). The contribution of the embedding polymethylmethacrylate (pMMA) 
and water vapour were corrected for each spectrum prior to baseline correction. Individual spectra 
were then subjected to curve fitting after second derivative using a commercially available software 
package (Grams/AI 8.0, Thermofisher scientific, Villebon sur Yvette, France) as previously reported 
[45]. The evaluated IR spectral parameters were (1) mineral-to-matrix ratio which reflects the degree 
of mineralization of the bone matrix, calculated from the ratio of integrated areas of the phosphate 1, 
3 band at 900-1200 cm
-1
 to the amide I band at 1585-1725 cm
-1
 [46]; (2) mineral maturity, which 
reflects the apatite size and perfection, calculated as the ratio of the relative intensity of subbands at 
1020 and 1030cm
-1
 of the phosphate band [47]; (3) the carbonate to phosphate ratio, which reflects 
the carbonate content in bone and determined by the ratio of integrated areas of the 2 CO3
2-
 region 
(850-890cm-1) to the 1, 3 phosphate band (900-1200cm
-1
) [47]; and (4) the collagen maturity index, 
determined as the relative ratio of subbands located at 1660 cm
-1
 and 1690 cm
-1
 of the amide I peak, 
was assessed [48]. Then, bone sections were demineralized with EDTA and reanalysed by FTIRM at 
the same location as described in detail elsewhere [45]. The collagen glycation index was investigated 
as the area ratio of the 1032 cm
-1
 subpeak over the amide I region. The collagen integrity index was 
determined as the area ratio of the 1338 cm
-1
 band over the amide II region.  
 
Nanoindentation 
Nanoindentation tests evaluated the mechanical properties at the tissue level. PMMA blocks used for 
FTIRM sections were polished to a 1-µm finish with diamond particles (Struers, France). Prior to 
nanoindentation testing, blocks were rehydrated for 24hrs in saline at 4°C. Prior to testing, the probe 
area function and instrument frame compliance were calibrated using a fused silica sample. Twelve 
indentations, at distance from canals, osteocyte lacunae and/or microcracks were randomly positioned 
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in cortical bone with a NHT-TTX system (CSM, Peseux, Switzerland) equipped with a Berkowitch 
diamond probe as the indenter and an optical system to control where indentation are positioned. 
Indentations were made up to a depth of 900 nm with a loading/unloading rate of 40mN/min. At 
maximum load, a holding period of 15 seconds was applied to avoid creeping of the bone material. 
The following material properties at the tissue-level, maximum load, indentation modulus, hardness 
and dissipated energy, were determined according to Oliver and Pharr [49].  
 
Bone mineral density distribution (BMDD) evaluation 
Quantitative backscattered electron imaging (qBEI) was employed to determine BMDD as previously 
reported [27]. QBEI experiments were performed on the same blocks as nanoindentation and FTIRM. 
Polymethylmethacrylate blocks were carbon-coated and observed with a scanning electron 
microscope (EVO LS10, Carl Zeiss Ltd, Nanterre, France) equipped with a five quadrant semi-
conductor backscattered electron detector. The microscope was operated at 20 keV with a probe 
current of 250 pA and a working distance of 15 mm. The backscattered signal was calibrated using 
pure carbon (Z=6, mean grey level = 25), pure aluminium (Z=13, mean grey level =225) and pure 
silicon (Z=14, mean grey level =253) standards (Micro-analysis Consultants Ltd, St Ives, UK). The 
cortical bone area was imaged at a 200X nominal magnification, corresponding to a pixel size of 0.5 
µm/pixel. Four images per samples were taken. Two variables were obtained from the bone mineral 
density distribution: Camean as the average calcium concentration and Cawidth as the width of the 
histogram at half maximum of the peak. Following this, the blocks were imaged at an X200 
magnification with a confocal microscope (Leica SP8, Leica, Nanterre, France) equipped with an 
argon laser at 488 nm and a hybrid GaAs detector (Leica) to find bone surface with double labels. 
Confocal images were superimposed on qBEI images in order to delineate new bone matrix formed 
during the time-course of the study. Using ImageJ 1.49v, a straight line (4 pixel width) perpendicular to 
the mineralization front across the new bone structural unit with a step size of 0.5µm was drawn on 
qBEI image. The calcium content was plotted vs. distance of mineralization front. These plots show a 
biphasic aspect with fast mineralization process close to the mineralization front followed by a slow 
mineralization process. The two mineralization processes were then analysed by linear curve-fitting 
with a lab-made routine in Excel 2010 (Microsoft, Issy-les-Moulineaux, France). Caturn was determined 
as the calcium concentration where the fast mineralization process was changing to the slow 
mineralization process as described by Roschger et al., [50].  
 
Statistical analysis 
Results were expressed as mean ± standard error of the mean (SEM). Analysis of variance (ANOVA) 
was used to compare overall difference among the three groups, followed by t-test when significant 
differences were detected using GraphPad Prism 5.0 (GraphPad Software Inc, La Jolla, CA). 
Differences at p<0.05 were considered to be significant.  
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RESULTS 
[D-Ala²]GIP-Oxm exerts modest effects on metabolic parameters 
Saline treated db/db mice exhibited a severe form of diabetes with plasma glucose concentrations > 
30 mmol/l (Table 2). Treatment with [D-Ala
2
]GIP-Oxm for 21 days had no significant effect on body 
weight or food intake in diabetic mice (Table 2). Non-fasting glucose concentrations in [D-Ala
2
]GIP-
Oxm-treated diabetic mice were reduced from day 10 onwards, however the values did not reach 
statistical significance (Supplementary Figure 1). On the other hand, plasma insulin levels were 
significantly increased on day 21 (3-fold, p<0.01) in mice treated with [D-Ala
2
]GIP-Oxm compared to 
diabetic saline controls. As shown in Table 2, once daily administration of [D-Ala
2
]GIP-Oxm had no 
significant effect on glucose tolerance or insulin response to glucose loading (Table 2).  
 
[D-Ala²]GIP-Oxm had no effect on body composition and bone mass assessed by DEXA 
Diabetic mice had significantly higher percentage of body fat compared to lean littermates (70% 
increase, p<0.01, Table 2). Treatment with [D-Ala
2
]GIP-Oxm had no significant effect on total fat mass 
in diabetic mice. There were no differences in BMD and BMC at regions of interest between [D-
Ala
2
]GIP-Oxm and saline-treated diabetic mice (Table 2). However, diabetic mice exhibited a 
significant decrease in whole body BMD (-24%, p<0.001) and BMC (- 50-59%, p<0.001) as well as at 
lumbar (BMD: 33 - 38% decrease, p<0.001; BMC: 53 - 63% decrease, p<0.001) and tibia (BMD: 21 - 
26% decrease, p<0.001; BMC: 45% decrease, p<0.001) compared to control mice. 
 
[D-Ala
2
]GIP-Oxm exerted a modest effect on bone strength at the organ level in diabetic mice 
We next investigated whether [D-Ala²]GIP-Oxm could reverse the reduced bone strength observed in 
diabetic mice. Figure 1A represents examples of load/deformation curves that were recorded in saline-
treated controls, saline- and [D-Ala²]GIP-Oxm-treated diabetic mice. All study parameters were 
significantly decreased in saline-treated diabetic mice as compared with saline-treated control mice 
(Figure 1B). On the other hand, [D-Ala²]GIP-Oxm-treated diabetic mice exhibited significant 
augmentations in ultimate displacement (96%, p<0.01) and work-to-failure (90%, p<0.01) as compared 
to saline-treated diabetic controls.  
 
[D-Ala
2
]GIP-Oxm ameliorated trabecular microarchitecture in diabetic mice  
Trabecular bone microarchitecture was investigated at the proximal metaphysis of the tibia. Figure 2A 
shows 3D-models of trabecular bone in saline-treated controls and both saline- and [D-Ala²]GIP-Oxm-
treated diabetic mice. These models suggest that trabecular bone mass is reduced in saline-treated 
diabetic mice as compared with normal control mice. However, [D-Ala²]GIP-Oxm seemed to partially 
preserve trabecular bone mass. Indeed, all microarchitectural parameters indicated a deterioration of 
the trabecular bone network in saline-treated diabetic mice as compared with saline-treated controls 
(Figure 2B). On the other hand, treatment of diabetic mice with [D-Ala²]GIP-Oxm significantly 
prevented the degradation in  BV/TV (20% vs. saline-treated diabetic mice, p<0.05), Tb.Th (11%, 
p<0.05), and Tb.Sp (-12%, p<0.05). Bone histomorphometry revealed a significant augmentation in 
N.Oc/B.Pm (300%, p<0.01) and a non-significant increase in BFR/BS (44%, p=0.22) in saline-treated 
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diabetic animals as compared with saline-treated controls. In contrast, [D-Ala²]GIP-Oxm-treated 
diabetic animals presented with significant reductions in N.Oc/B.Pm (-31%, p<0.05) and BFR/BS (-
46%, p<0.05) as compared with saline-treated mice. Marrow adiposity was significantly augmented in 
saline- and GIP-Oxm-treated diabetic mice as compared with saline-treated controls (p<0.05).  
 
[D-Ala
2
]GIP-Oxm did not improve cortical microarchitecture in diabetic mice 
Cortical bone microarchitecture was dramatically altered in diabetic animals as demonstrated in the 3D 
models in Figure 3A. Indeed, total cross-sectional area, cortical bone area, cortical area fraction, 
cortical thickness and cortical porosity were significantly lowered in saline-treated diabetic mice as 
compared with normal saline-treated controls (Figure 3B). However, despite small increases in Ct.Ar, 
Ct.Ar/Tt.Ar and Ct.Th in [D-Ala²]GIP-Oxm-treated diabetic mice, none of these parameters reached 
statistical significance. At the cellular level, Ct.MAR was significantly elevated in saline-treated diabetic 
animals compared with saline-treated controls (130%, p<0.001). Similarly, N.Oc/Es.S (187%, p<0.05) 
and N.Oc/Ps.S (100%, p<0.05) were elevated in saline-treated diabetic animals compared with saline-
treated controls. In contrast, short-term treatment with [D-Ala²]GIP-Oxm significantly reduced Ct.MAR 
(-39%, p<0.05) and N.Oc/Es.S (-51%, p<0.05) in diabetic mice as compared to saline-treated animals. 
N.Oc/Ps.S was also reduced in [D-Ala²]GIP-Oxm-treated diabetic mice (-42%, p=0.10), although this 
parameter did not reach statistical significance.  
  
[D-Ala
2
]GIP-Oxm improved bone strength at the tissue level in diabetic mice 
As several mechanical parameters were improved at cortical site without apparent effects of [D-
Ala²]GIP-Oxm on microarchitectural properties, we investigated the mechanical behaviour at the tissue 
level (Figure 4). Hardness, indentation modulus and dissipated energy were significantly decreased in 
saline-treated diabetic mice as compared with saline-treated control animals. [D-Ala²]GIP-Oxm 
resulted in higher values for hardness (25%, p<0.05) and indentation modulus (8%, p<0.05) as 
compared with saline-treated diabetic animals. [D-Ala²]GIP-Oxm had no effects on improving 
dissipated energy (p=0.33).  
 
[D-Ala
2
]GIP-Oxm did not profoundly modify the bone mineral density distribution in diabetic 
mice 
The tissue mineral density distribution was evaluated by qBEI at cortical site. The calcium content of 
the entire width of cortical bone was mapped and it appeared that diabetic mice presented with greater 
calcium content as compared to control animals (Figure 5A). Camean and Cawidth were significantly 
augmented in saline-treated diabetic mice as compared to saline-treated control animals (Figure 5B). 
[D-Ala²]GIP-Oxm did not modify these profiles. As the treatment period was relatively short, we next 
examined calcium content in newly-formed bone. The biphasic profile of calcium increase, assessed 
by the distance from mineralization front, is presented Figure 5C. Caturn values were significantly 
increased in saline-treated diabetic animals as compared to saline-treated controls (20%, p<0.01). On 
the other hand, [D-Ala²]GIP-Oxm significantly reduced Caturn values(-10%, p<0.01) as compared with 
saline-treated diabetic controls, to achieve levels similar to those of normal mice. We then ascertained 
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whether collagen orientations were modified in db/db mice and indeed, saline-treated db/db mice 
exhibited a significant 82% reduction in this parameter along the long axis of the bone as compared 
with control animals (p<0.01; Figure 5D). On the other hand, GIP-Oxm-treated db/db mice exhibited 
similar collagen orientations as evidenced in control animals.    
 
[D-Ala
2
]GIP-Oxm improved tissue material properties at bone formation site in diabetic mice  
Investigation of tissue material properties at bone formation site was investigated by FTIRM (Figure 6). 
Although the mineral/matrix ratio followed a similar pattern as observed for Caturn, this parameter was 
not significantly different between the three groups of animals. Mineral maturity and 
carbonate/phosphate were similar in the three groups of animals. However, saline-treated diabetic 
mice presented with significant modifications in collagen glycation (25%, p<0.05) and collagen 
maturity (-18%, p<0.01) compared with control animals. Treatment with [D-Ala²]GIP-Oxm significantly 
reduced collagen glycation (-13%, p<0.05) and significantly increased collagen maturity (17%, p<0.05) 
compared with saline-treated diabetic mice.  
 
DISCUSSION 
In this study, an established genetically-inherited model of obesity and diabetes, the diabetic (db/db) 
mouse, was employed to examine the effects of [D-Ala
2
]GIP-Oxm on bone strength and quality at the 
organ and tissue levels. These mice presented with significant reductions in cortical bone strength at 
the organ and tissue levels, lower BMD values at the spine, tibia and whole body, alterations of 
microarchitectural properties of trabecular and cortical bone as well as alterations of tissue material 
properties materialized by modifications of mineral and collagen compartments. Despite the relatively 
short time involved, treatment of db/db mice with [D-Ala²]GIP-Oxm for 21 days improved bone strength 
at the organ and tissue levels, improved trabecular but not cortical microarchitectural properties and 
improved tissue material properties. 
 
As expected, 12 week old db/db mice displayed increased body weight, enhanced fat mass moderate 
hyperinsulinemia and severe hyperglycaemia, with substantial glucose intolerance [10, 11]. In contrast 
to a recent study in high-fat fed mice, [D-Ala
2
]GIP-Oxm administration had no significant effect on 
body weight, non-fasting plasma glucose or glucose tolerance in db/db mice [34]. However, values 
tended to be lower and non-fasting plasma insulin concentrations were significantly increased on day 
20 in treated db/db mice. This difference in efficacy with high fat fed mice reflects the greater severity 
of diabetes in the present study, as even after food was withdrawn for 18 h, plasma glucose levels in 
db/db mice were still very high at around 22.5 mmol/l. We do not believe that triple agonism of 
glucagon as well as GLP-1 and GIP receptors is the reason for lack of effect in these mice with beta-
cell degeneration, because we have recently shown that a different stable Oxm analogue, (D-
Ser
2
)Oxm[Lys
38
PAL], can ameliorate type 1 diabetes in streptozotocin treated mice when administered 
twice daily [51]. Thus, it seems likely that a greater dose is required in db/db mice to counter the 
diabetes. However, absence of substantial changes in glycaemic control allows us to evaluate the 
direct effects of [D-Ala²]GIP-Oxm on bone which are independent of metabolic change.  
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Insulin is known to induce bone formation and previously, we clearly revealed that hypoinsulinemia in 
STZ-diabetic mice contributes to bone loss [23, 52]. In the present study using leptin receptor-deficient 
db/db mice, we found that total, tibia and lumbar bone mineral density together with bone mineral 
content were significantly decreased in db/db mice despite hyperinsulinemia. These results support 
earlier observations of reduced BMD and BMC in mice lacking leptin receptors [2]. One of the possible 
contributing factors to the reductions of bone mass in db/db mice is loss in leptin signalling. 
Osteoblasts and adipocytes are derived from the same progenitors, marrow stromal cells (MSCs), and 
interestingly, leptin receptors are expressed on human MSCs [7]. In addition, the ability of leptin to 
dose-dependently enhance osteoblastic protein expression and reduce adipocyte biomarkers in 
cultures of MSCs, emphasises the importance of leptin in controlling differentiation pathways of MSC 
precursors towards osteoblasts or adipocytes [7]. As a result of defective leptin signal transduction, 
differentiation of precursors is shifted to adipogenesis, resulting in increased body weight and bone 
loss, leading to bone impairments. This was confirmed in the present study by an increase in marrow 
adiposity in db/db mice irrespective of treatments. In our study, a higher number of osteoclasts was 
found either at the surface of trabecula and on the endosteal and periosteal envelopes. This is in 
agreement with the work of Holloway and co-workers who reported that leptin inhibited osteoclast 
differentiation [53]. As such, deficiency in leptin signalling may enhance generation of osteoclasts and 
increase osteoclastic bone resorptive activity, resulting in further bone loss, as evidenced in the 
present study. However, the non-significant increase in BFR/BS in trabecular bone and Ct.MAR in 
cortical bone seem to argue against an anabolic action of leptin and might be secondary to higher 
bone resorption or due to obesity and diabetes itself. [D-Ala
2
]GIP-Oxm did not have a remarkable 
effect on BMD and BMC at any sites of db/db mouse when compared to saline-treated db/db controls. 
This is not necessarily surprising given the relatively short observation period, and it is plausible that 
extended treatment with [D-Ala²]GIP-Oxm would have resulted in changes picked up by DEXA 
measurements.  
 
Previous studies in leptin signalling deficient diabetic animals, including ZDF rats, fa/fa rats and db/db 
mice, have reported lower bone strength at the organ level [5, 54-56]. In the present study, we 
evidenced a reduction in bone strength at the organ level with significant lower values for ultimate 
load, ultimate displacement, stiffness and work-to-failure. In diabetic db/db mice, load deformation 
curves evidenced a bone that is more brittle with little plastic deformation as compared to saline-
injected control animals. Short-term treatment with [D-Ala²]GIP-Oxm in diabetic animals was capable 
of preserving plastic deformation in a manner comparable to saline-injected normal control mice as 
evidenced by similar ultimate displacement values. This triple agonist also improved work-to-failure in 
diabetic mice, likely by preserving plastic deformation, although ultimate load and stiffness were 
unchanged as compared to saline-injected diabetic mice.  
 
Further assessment of trabecular and cortical microarchitecture revealed that db/db mice had 
profound alterations of these two properties. Although controversy on the anabolic or catabolic actions 
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of leptin signalling have been reported in the past years, our results are in agreement with the recent 
evidence provided by Williams and et al., who observed similar modifications of trabecular and cortical 
microarchitecture in db/db mice [5]. Cellular assessment at both compartment suggested that diabetic 
mice present with a higher bone turnover. Microstructural examination demonstrated that [D-Ala²]GIP-
Oxm was capable of improving trabecular microarchitecture but failed to evidence any effects on 
cortical microarchitecture. At the cellular level, the effect of [D-Ala²]GIP-Oxm, seemed to be due to a 
reduction in bone turnover. In the light of bone strength improvement observed in 3-point bending 
experiments in [D-Ala²]GIP-Oxm-treated animals, it is likely that the effect of this triple agonist is on 
tissue material properties.  
 
Previous investigations reported a lower elastic modulus at the tissue level in db/db mice [5]. In the 
present study, we also evidenced lower indentation modulus, but also reductions in hardness and 
dissipated energy in saline-treated diabetic mice versus saline-injected normal control mice. 
Interestingly, treatment with [D-Ala²]GIP-Oxm improved hardness and indentation modulus, illustrating 
clear effects of this triple agonist on tissue material properties in diabetic mice. It is noteworthy that we 
previously reported that animals lacking either the GIP, GLP-1 or both incretin receptors presented 
with alterations of bone strength at the tissue level, supporting an important action of these gut 
hormones [21-23]. In order to ascertain what modifications of tissue material properties were ongoing 
in db/db mice, we examined the overall tissue mineral density distribution by qBEI. Unexpectedly we 
observed that saline-treated diabetic mice presented with higher mean calcium content and higher 
calcium heterogeneity as compared with controls. Regarding the apparent increase in bone turn-over 
at the cellular level, it seemed puzzling that the mean calcium content was increased. However, 
mathematical computed modelling of bone mineral density distribution revealed that the observed 
Gaussian pattern is possible only if two independent processes change, namely (i) the frequency of 
bone remodelling, that leads to a certain bone turn-over rate and (ii) the time course of matrix 
mineralization [57, 58]. Exact knowledge of the underlying mineralization process is still lacking, but it 
should be noted that once mineralization has started in the newly-formed bone matrix, the mineral 
content is rapidly increasing within few days up to 70% of its final value and then reaches a plateau 
with a much slower increase in mineral content [59, 60]. The calcium content at which matrix 
mineralization turns from rapid to slow is accessible by qBEI and is referred to as Caturn [50]. 
Investigations of Caturn in newly-formed bone evidenced that in saline-treated diabetic db/db mice, this 
parameter was significantly increased as compared with normal mice, suggesting that matrix 
mineralization had changed. Similarly, [D-Ala²]GIP-Oxm-treated diabetic animals presented with 
higher mean calcium content and heterogeneity in the matrix. However, in regard to the lower bone-
turnover and lower Caturn values, this suggests that [D-Ala²]GIP-Oxm should result in higher mean 
calcium content and lower heterogeneity. Nevertheless, as the treatment period was short, and given 
that most of the bone matrix had been formed and mineralized before administration of [D-Ala²]GIP-
Oxm, it is likely that the increase in mean calcium content and calcium heterogeneity reflects 
modifications of matrix mineralization observed in saline-injected diabetic mice. Longer term studies 
would be required to fully assess the effects of [D-Ala²]GIP-Oxm on matrix mineralization.  
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In view of the relatively short-duration of treatment, we then assessed tissue material properties at 
bone formation site. Diabetic mice did not exhibit any modification of the mineral compartment as 
compared to saline-injected controls or [D-Ala²]GIP-Oxm treated mice. The lack of significant 
modifications in the mineral-to-matrix ratio seems in contradiction with the observed variations in 
Caturn. However, it is noteworthy that saline-treated and [D-Ala²]GIP-Oxm-treated diabetic mice exhibit 
trends to the same changes in matrix-to-mineral ratios as observed for Caturn. The differences between 
these two parameters, that somehow investigate the same mineralization process, might reside with 
the spatial resolution of qBEI and FTIRM. In qBEI, with our experimental settings, spatial resolution 
was 0.5 µm. However, in FTIRM, mineral signal is best around 900-1200 cm
-1
 and hence at these 
wavenumbers, the spatial resolution is around ~10 µm. Investigations of the collagen compartment 
revealed that saline-treated diabetic mice presented with increased collagen glycation and reduced 
collagen maturity as compared to saline-injected controls and that these modifications were reversed 
by [D-Ala²]GIP-Oxm. These findings are in agreement with previous studies investigating collagen 
properties in connection with GIP and GLP-1 signalling [21-23, 27, 61]. It is likely that these 
modifications of the collagen compartment participated to the improved bone strength at the tissue but 
also organ level. In the present study, collagen glycation has been reported as the ratio between the 
sub-band located at 1032 cm
-1
 over Amide I. This ratio has been demonstrated specific of collagen 
glycation as compared with the less validated 900-1200 cm
-1
/Amide I that takes into account sub-
bands representative of protein phosphorylation and glycosaminoglycans [45]. However, the 
1338/Amide II ratio was unchanged between the three groups of animals. Although the significance of 
this ratio remains to be elucidated, it has been previously demonstrated that the 1338 cm
-1
 peak is 
greatly affected by collagenase treatment and seems to be related to collagen helical integrity in bone 
and other connective tissues [45, 62, 63]. Furthermore, collagen orientations was altered in saline-
treated db/db mice and restored in GIP-Oxm-treated db/db mice as compared with controls and these 
results are in agreement with previous observations reported by others [64, 65]. On the other hand, 
further work will be required to ascertain whether crack propagation and toughness are also improved 
in response to [D-Ala²]GIP-Oxm.  
 
In conclusion, this study reveals that bone strength both at the organ and tissue levels is detrimentally 
altered in db/db mice and accompanied by profound modifications of microarchitectural and material 
properties. Moreover, the DPP-4 resistant [D-Ala
2
]GIP-Oxm analogue elicits significant beneficial 
effects on trabecular microarchitecture and cortical tissue material properties that resulted in 
improvement in bone strength at the tissue and organ level. The positive effects of triple-activation of 
GIP, GLP-1 and glucagon receptors by [D-Ala
2
]GIP-Oxm on bone quality in db/db mice, independent 
of significant changes in glycaemic status, provides additional evidence for including incretins as 
possible new therapeutic strategies for bone-related diseases.  
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FIGURE LEGENDS 
Figure 1:  Assessment of bone strength at the organ level in saline- and [D-Ala²]GIP-Oxm-
treated diabetic mice by three point bending. (A) Examples of load-displacement 
curves. Saline-injected controls, black line; saline-treated diabetic mice, dashed line; 
[D-Ala²]GIP-Oxm-treated diabetic mice, grey line. (B) Mechanical parameters recorded 
at the end of the study. ** and ***: p<0.01 and p<0.001 vs. saline-injected controls, 
respectively. ##: p<0.01 vs. saline-treated diabetic mice.   
Figure 2:  Alterations of trabecular microarchitecture in saline- and [D-Ala²]GIP-Oxm-
treated diabetic mice. (A) Three dimensional models of trabecular microarchitecture 
recorded at the proximal tibia metaphysis. (B) Trabecular microarchitecture 
parameters. *, ** and ***: p<0.05, p<0.01 and p<0.001 vs. saline-injected controls, 
respectively. # and ##: p<0.05 and p<0.01 vs. saline-treated diabetic mice, 
respectively. 
Figure 3:  Alterations of cortical microarchitecture in saline- and [D-Ala²]GIP-Oxm-treated 
diabetic mice. (A) Three dimensional models of cortical microarchitecture recorded at 
the tibia midshaft. (B) Cortical microarchitectural parameters. *, ** and ***: p<0.05, 
p<0.01 and p<0.001 vs. saline-injected controls, respectively.  
Figure 4:   Assessment of bone strength at the tissue level in saline- and [D-Ala²]GIP-Oxm-
treated diabetic mice by nanoindentation. * and **: p<0.05 and p<0.01 vs. saline-
injected controls, respectively. #: p<0.05 vs. saline-treated diabetic mice.  
Figure 5:  Bone mineral density distribution (BMDD) in saline- and [D-Ala²]GIP-Oxm-
treated diabetic mice. (A) Representative calcium map of saline-injected controls, 
saline- and [D-Ala²]GIP-Oxm-treated diabetic mice. (B) Characterization of BMDD by 
Camean and Cawidth. (C) Bone mineralization profile and associated Caturn value. (D) 
Birefringent collagen area showing collagen orientation along the longitudinal axis. * 
and **: p<0.05 and p<0.01 vs. saline-injected controls, respectively. ##: p<0.01 vs. 
saline-treated diabetic mice. 
Figure 6:  Tissue material properties assessed at bone formation site in saline- and [D-
Ala²]GIP-Oxm-treated diabetic mice. * and **: p<0.05 and p<0.01 vs. saline-injected 
controls, respectively. #: p<0.05 vs. saline-treated diabetic mice.  
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Table 1: Characteristics of [D-Ala²]GIP-Oxm 
Peptide Sequence 
In vitro DPP-4 
resistance time (h) 
% of cAMP production at 
GIPr GLP-1r GcgR 
GIP YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ 2.2 100 - - 
Oxyntomodulin HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA 9.3 - 100 100 
[D-Ala²]GIP-Oxm Y[D-Ala]EGTFISDYSKYLDSRRAQDFVQWLMNTKRNRNNIA >24 95 77 83 
 
Resistance of peptides to degradation by DPP-4 (5 mU) was measured (n=3) following 0, 2, 4 and 8 h incubations. Reaction products were subsequently analysed by HPLC. 
For in vitro cAMP production studies, peptides (10
−6
 M) were incubated (20 min; n=4) with GIP-, GLP-1- and glucagon-R transfected cells [34] and cAMP generation measured 
by ELISA and presented as a percentage of respective control. Abbreviations: DPP-4, dipeptidyl peptidase 4; GIPr, GIP receptor; GLP-1r, glucagon-like peptide-1 receptor; 
GcgR, glucagon receptor 
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Table 2: Metabolic, compositional and densitometric parameters  
 Saline 
controls 
Saline 
diabetic 
[D-Ala²]GIP-Oxm 
diabetic 
Non fasting glucose (mM) 5.1 ± 0.5 31.5 ± 0.8 ** 30.4 ± 0.8 ** 
Non fasting insulin (ng/ml) 1.1 ± 0.2 0.03 ± 0.01 ** 0.09 ± 0.03 **
,ΔΔ
 
Plasma glucose AUC (mM.min) 205 ± 14.2 699.6 ± 133.3 552.5 ± 50.7 
Plasma insulin AUC (ng/ml.min) 38.2 ± 9.8 2.1 ± 0.6 3.2 ± 0.9 
Body weight (g) 25.7 ± 0.7 39.6 ± 2.8 ** 38.7 ± 1.5 ** 
Fat mass (%) 13.2 ± 0.8 45.2 ± 2.7 ** 44.8 ± 1.8 ** 
Whole body BMD (g/cm²) 0.052 ± 0.001 0.039 ± 0.000 ** 0.040 ± 0.001 ** 
Whole body BMC (g) 0.493 ± 0.010 0.201 ± 0.045 ** 0.247 ± 0.013 ** 
Lumbar BMD (g/cm²) 0.064 ± 0.003 0.043 ± 0.002 ** 0.039 ± 0.001 ** 
Lumbar BMC (g) 0.040 ± 0.001 0.019 ± 0.002 ** 0.015 ± 0.001 ** 
Tibia BMD (g/cm²) 0.059 ± 0.001 0.044 ± 0.001 ** 0.047 ± 0.002 ** 
Tibia BMC (g) 0.020 ± 0.001 0.010 ± 0.000 ** 0.011 ± 0.000 ** 
 
Parameters were measured after 28 days treatment with saline vehicle or [D-Ala²]GIP-Oxm (50 nmol/kg) in lean control or db/db diabetic mice. For glucose 
tolerance, glucose (18 mmol/kg body weight) was administered in non-fasted mice and 0-60 min plasma glucose and insulin area under the curve (AUC) 
values calculated. All BMD and BMC measurements were determined using a Lunar PIXImus DEXA scanner on day 28. Values are mean ± SEM for ten mice. 
** p<0.01 vs. saline-treated control mice. 
ΔΔ
 p<0.01 vs. saline-treated db/db diabetic mice. Abbreviations: BMD, Bone mineral density; BMC, Bone mineral 
content; ND, not determined 
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Fig. 2  
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Fig. 3  
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Fig. 4  
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Fig. 5  
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Fig. 6  
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HIGHLIGHTS 
 Leptin receptor-deficient mouse presented with dramatic alterations of bone strength at both 
the organ and tissue level 
 Leptin receptor-deficient mouse exhibited deteriorations of trabecular and cortical 
microarchitectures 
 Treatment with [D-Ala²]GIP-Oxm preserved trabecular bone mass and thickness 
 Treatment with [D-Ala²]GIP-Oxm improved collagen glycation and maturity 
